“Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s47. doi:10.25251/skin.6.supp.47.